ESMO 2025 | The future impact of claudin 18.2-targeted therapies in gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, highlights the potential clinical impact of claudin 18.2 as a biomarker in treating patients with gastric cancer. The advent of novel treatment combinations such as zolbetuximab with chemotherapy have expanded the target population, but further follow-up will be needed to assess the treatment’s effectiveness. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Claudin has already established a biomarker targeting gastric cancer, but the current threshold is 75% to treat patients by zolbetuximab plus chemotherapy. So still, it is better to expand the population to target lower claudin 18.2 expression with additional effective treatment. I believe zolbetuximab could be the best candidate, so that’s why we combine with chemotherapy and checkpoint inhibitors...
Claudin has already established a biomarker targeting gastric cancer, but the current threshold is 75% to treat patients by zolbetuximab plus chemotherapy. So still, it is better to expand the population to target lower claudin 18.2 expression with additional effective treatment. I believe zolbetuximab could be the best candidate, so that’s why we combine with chemotherapy and checkpoint inhibitors. Still, we need to follow up additional patients to exactly assess how the treatment is effective. We would consider targeting these claudin populations in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
